Skip to Main Content
Beta test
our new site.
(
NLM Technical Bulletin
)
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Panitumumab Plus Pemetrexed and Cisplatin (PemCisP) Versus PemCis in the First-line Treatment of Patients With Non-small Cell Lung Cancer
This study has suspended participant recruitment.
( the DSMB stopped the trial due to unacceptable side effects in the experimental arm which has not yet been verified )
Study NCT01088620 Information provided by WiSP Wissenschaftlicher Service Pharma GmbH
First Received on March 16, 2010. Last Updated on March 13, 2013
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Carcinoma, Non-Small-Cell Lung
Additional conditions recognized in this trial
Carcinoma
Lung Neoplasms
More general conditions related to this trial
Bronchial Neoplasms
Carcinoma, Bronchogenic
Lung Diseases
Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Glandular and Epithelial
Respiratory Tract Diseases
Respiratory Tract Neoplasms
Thoracic Neoplasms
Interventions listed in this trial
Panitumumab
Pemetrexed
Cisplatin
Additional drug interventions recognized in this trial
Antibodies, Monoclonal
More general drug interventions related to this trial
Antimetabolites
Antimetabolites, Antineoplastic
Antineoplastic Agents
Enzyme Inhibitors
Folic Acid Antagonists
Immunologic Factors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Radiation-Sensitizing Agents
Therapeutic Uses
Sponsors listed in this trial
WiSP Wissenschaftlicher Service Pharma GmbH
Gesellschaft fur Medizinische Innovation – Hamatologie und Onkologie mbH
Back to top of Main Content
